Docetaxel Chemotherapy of Korean Patients with Hormone-refractory Prostate Cancer: Comparative Analysis between 1st-line and 2nd-line Docetaxel.
10.3349/ymj.2008.49.5.775
- Author:
Jae Young JOUNG
1
;
In Gab JEONG
;
Kyung Seok HAN
;
Taek Sang KIM
;
Seung Ok YANG
;
Ho Kyung SEO
;
Jinsoo CHUNG
;
Kang Su CHO
;
Kang Hyun LEE
Author Information
1. Urologic Oncology Clinic, National Cancer Center, Goyang, Korea. uroonco@ncc.re.kr
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Prostate neoplasm;
chemotherapy;
docetaxel
- MeSH:
Aged;
Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use;
Humans;
Male;
Middle Aged;
Prostate-Specific Antigen/blood;
Prostatic Neoplasms/*drug therapy/mortality;
Retrospective Studies;
Taxoids/administration & dosage/adverse effects/*therapeutic use;
Treatment Outcome
- From:Yonsei Medical Journal
2008;49(5):775-782
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study was undertaken to investigate the outcomes associated with docetaxel treatment of Korean patients with hormone-refractory prostate cancer (HRPC) and to compare its clinical efficacies in 1st and 2nd-line settings. PATIENTS AND METHODS: This study was retrospectively performed and included 47 patients with HRPC. The 1st-line group consisted of 19 patients who had not undergone prior chemotherapy, and the 2nd-line group consisted of 28 patients who underwent prior chemotherapy. All patients were treated with 75mg/m2 IV docetaxel every 3 weeks and 5mg of prednisone twice daily with a continuous androgen blockade. RESULTS: Of 47 study subjects, 14 patients (29.8%) had > or = 50% PSA decline from baseline. PSA response was more common in the 1st-line group, but this was not statistically different (42.1% vs. 21.4%, p = 0.114). After a median follow up of 11 months (range, 6-24 months), the 1st-line group showed a longer time to PSA progression (4 vs. 2 months, p = 0.015) and survival (17 vs. 10 months, p = 0.037) than the 2nd-line group. In terms of toxicities, no difference was apparent between the 2 groups. CONCLUSION: In a 1st-line setting, docetaxel is an effective and tolerable agent for Korean HRPC patients, and that its efficacy is limited, although 2nd-line docetaxel is tolerable.
